Ixinity FDA Approval History
Last updated by Judith Stewart, BPharm on March 26, 2024.
FDA Approved: Yes (First approved April 29, 2015)
Brand name: Ixinity
Generic name: coagulation factor IX (recombinant)
Dosage form: for Injection
Company: Emergent BioSolutions Inc.
Treatment for: Hemophilia B
Ixinity (coagulation factor IX (recombinant)) is a clotting factor IX therapy used to prevent bleeding in patients with hemophilia B.
- Ixinity is indicated in adults and children with hemophilia B for:
- on-demand treatment and control of bleeding episodes
- perioperative management
- routine prophylaxis to reduce the frequency of bleeding episodes.
Ixinity is not indicated for induction of immune tolerance in patients with hemophilia B.
Development timeline for Ixinity
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
